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Background: This study was conducted as part of the Driving Reinvestment in Research and Development and
Responsible Antibiotic Use (DRIVE-AB) project and aimed to develop generic quality indicators (QIs) for respon-
sible antibiotic use in the inpatient setting.
Methods: A RAND-modified Delphi method was applied. First, QIs were identified by a systematic review. A comple-
mentary search was performed on web sites of relevant organizations. Duplicates were removed and disease and
patient-specific QIs were combined into generic indicators. The relevance of these QIs was appraised by a multidis-
ciplinary international stakeholder panel through two questionnaires and an in-between consensus meeting.
Results: The systematic review retrieved 70 potential generic QIs. The QIs were appraised by 25 international
stakeholders with diverse backgrounds (medical community, public health, patients, antibiotic research and de-
velopment, regulators, governments). Ultimately, 51 QIs were selected in consensus. QIs with the highest
relevance score included: (i) an antibiotic plan should be documented in the medical record at the start of the
antibiotic treatment; (ii) the results of bacteriological susceptibility testing should be documented in the medical
record; (iii) the local guidelines should correspond to the national guidelines but should be adapted based on
local resistance patterns; (iv) an antibiotic stewardship programme should be in place at the healthcare facility;
and (v) allergy status should be taken into account when antibiotics are prescribed.
Conclusions: This systematic and stepwise method combining evidence from literature and stakeholder opinion
led to multidisciplinary international consensus on generic inpatient QIs that can be used globally to assess the
quality of antibiotic use.
Introduction
The loss of effectiveness of many antibiotics as a consequence
of the emergence of antibiotic resistance has evolved to be-
come a major threat to global public health. Unfortunately,
this phenomenon coincides with a dry pipeline in antibiotic
research and development (R&D).1 The repercussions for pa-
tient care include increased mortality and limited effective
therapy options for MDR and hospital-acquired infections.2
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In addition, treatment failure caused by antibiotic resist-
ance has considerable financial consequences through, for ex-
ample, prolonged hospital stay or more expensive antibiotic
therapy.2
While all antibiotic use drives the emergence and dissemination
of resistance to some degree, a major aggravating force is the in-
appropriate use of antibiotics.3 Therefore, reducing both overall
antibiotic consumption and inappropriate use is a strategy to slow
the pace of the emergence of resistant bacteria.4–6 This strategy,
commonly referred to as antibiotic stewardship, aims to measure
and to improve antibiotic use.7 In order to be successful, antibiotic
stewardship programmes (ASPs) should comprise distinct tools for
measuring both the quantity and quality of antibiotic use.
Measuring (in)appropriateness of healthcare is typically done
using quality indicators (QIs), defined as ‘measurable elements of
practice performance for which there is evidence or consensus
that they can be used to assess the quality, and hence change the
quality of care provided’.8 QIs of appropriate antibiotic use are
valuable tools for ASPs as they guide the selection of improvement
targets as well as help to establish the effectiveness of improve-
ment interventions.9
The Driving Reinvestment in Research and Development and
Responsible Antibiotic Use (DRIVE-AB) research consortium pro-
poses the following definitions to distinguish between the assess-
ment of quality and quantity of antibiotic use. A QI reflects the
degree to which antibiotic use is correct or appropriate while, in
contrast, a quantity metric reflects the volume or the costs of anti-
biotic use.10 Therefore, the QI has a value on its own while the
quantity metric only gains value when comparisons are made be-
tween, for example, wards, hospitals or countries.
The DRIVE-AB project aims at reaching consensus on a stand-
ard for ‘responsible antibiotic use’, including QIs, between a large
variety of stakeholders involved in antibiotic use: from prescribers
through producers and regulators to patients. Indeed, the large
scale of societal implications of the loss of antibiotic effectiveness
as a result of resistance development requires combined cross-
disciplinary efforts throughout the whole of society.
The aim of this study was to develop generic QIs for the inpa-
tient setting taking into account different perspectives, including
the medical community, public health, patients, developers and
producers (antibiotic R&D), regulators and governments.
Altogether, the QIs should serve as guiding principles for antibiotic
use in the inpatient setting across diverse socioeconomic settings.
Materials and methods
A four-step RAND-modified Delphi method,11–13 an iterative process of rat-
ing and soliciting expert input with multiple opportunities for feedback, was
applied to develop generic QIs for antibiotic use in the inpatient setting. The
consensus procedure combined the individual opinions of four groups of
stakeholders. All the stakeholders consented to participate in the study and
were aware that their answers would be used for research. The consensus
procedure took place from mid-August 2015 till the end of January 2016.
Step 1 – Literature and web site search
A systematic review was performed in the MEDLINE database (since 1966)
to identify papers describing inpatient QIs for antibiotic use. An inpatient
was defined as a patient who is admitted to a hospital or healthcare facility
for treatment. A healthcare facility was defined as any location where
healthcare is provided, ranging from small clinics to hospitals. The search
was performed on 5 February 2015. The search strategy is detailed in
Figure S1 (available as Supplementary data at JAC Online). The aim was to
identify QIs for antibiotic use that were either evidence-based (literature re-
view, evidence-based guidelines) or consensus-based (formal and vali-
dated consensus, such as Delphi). Papers were included when written in
English, on the use of systemically administered antibiotics drugs and
when describing QIs for antibiotic use in the inpatient setting. Papers on the
use of antiviral, antifungal, antiparasitic or antituberculosis drugs were
excluded. Papers were also excluded when describing QIs for rare or orphan
diseases, as reported by Orphanet.14 Finally, papers of which the full-text
version was not accessible from Google ScholarVR or one of the following
libraries were also excluded: French National Institute of Health and
Medical Research (INSERM), Radboud University Medical Center, University
of Rijeka, University of Antwerp, University of Geneva, University of Leuven
and University of Lorraine.
Two researchers (A. A. M. and I. C. G.) independently examined all titles
and abstracts to select papers describing QIs for the inpatient setting using
the DistillerV
R
software (Evidence Partners, Ottawa, Canada). Any disagree-
ment on inclusion or exclusion of studies was resolved through discussion
with a third author (M. E. H.). If no abstract was available or information was
lacking for eligibility assessment, papers were selected for full-text screen-
ing. The exclusion of papers based on full-text screening was performed by
one author (A. A. M.) and validated by a senior researcher (I. C. G.).
A complementary search was performed on English web sites of rele-
vant (inter)national organizations and institutions active in the field of anti-
biotic stewardship, quality improvement and/or public health. Relevant
web sites were selected in consensus by the authors, all working in the field
of infectious diseases and/or antibiotic stewardship. Relevant sections of
the web sites were searched by one reviewer (A. A. M.) using the search
terms ‘indicator’ and/or ‘antibiotic/antimicrobial’.
The data extraction of QIs of antibiotic use was performed by one re-
searcher (A. A. M.) using a standardized form. For the papers identified by
the systematic review, the extraction process was repeated by the same re-
searcher a second time for 10% of the references. Similarly, the data ex-
traction from web sites was performed by the same researcher twice. The
extracted QIs were then clustered into different non-overlapping logical
themes based on the elements of the definition of responsible use.15 When
a QI could be allocated to more than one theme, the predominant theme
was chosen in consensus between two authors (A. A. M. and I. C. G.).
Duplicates were removed. Overlapping QIs were then aggregated and,
when applicable, disease- and patient-specific QIs were made more gen-
eric. Generic was defined as general and applicable to a large group of pa-
tients, not specific to any particular disease, country region or inpatient care
setting.16 When needed, QIs were rephrased as a recommendation. The
clustering, aggregation and rephrasing steps were undertaken in consensus
between four authors (A. A. M., I. C. G., J. S. and M. E. H.).
Step 2 – First questionnaire
International stakeholders were invited by e-mail to participate.
Stakeholders were invited based either on demonstrated experience and
expertise in the topic of antibiotic use and/or stewardship, or in different
perspectives of antibiotic use. Invited stakeholders originated from various
countries across all continents. Stakeholders among the extended interna-
tional network of academic and European Federation of Pharmaceutical
Industries and Associations (EFPIA) partners of the DRIVE-AB project were
solicited. Fifty-two stakeholders amongst four different groups, aiming at
representing all parties involved in antibiotic use, were invited: medical
community (n"15); public health and patients (n"12); antibiotic R&D
(n"14); and payers, policy makers, governments and regulators (n"11).
A digital web-based questionnaire, with the potential inpatient QIs iden-
tified by the literature and web site searches, was designed using
SurveyMonkeyV
R
(Palo Alto, CA, USA). Together with the invitation e-mail,
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stakeholders received a document providing the scientific references for
each of the identified QIs. The stakeholders were asked to appraise the
relevance of each indicator for assessing the quality of antibiotic use.
The 70 potential QIs were categorized and presented to the stakeholders.
The assessment of relevance was done using a nine-point Likert scale
(1" clearly not relevant, 9" clearly relevant). Stakeholders could also se-
lect the ‘cannot assess’ answer. Median scores were analysed across the
four stakeholder groups. Relevance scores were interpreted as described
elsewhere.17,18 If the QI had a median8 and if there was agreement be-
tween the stakeholders, the QI was selected. If the QI had a median8 in
combination with stakeholder disagreement, the QI was labelled for dis-
cussion. If the QI had a median ,8, the QI was rejected. Agreement and
disagreement were defined as 70% and ,70% of the scores being in the
upper tertile (score 7–9), respectively.17,18 Stakeholders could comment on
each indicator as well as propose new QIs. Newly proposed QIs that did not
present any overlap with other QIs were selected for discussion in the con-
sensus meeting.
Step 3 – Consensus meeting
Stakeholders that participated in the first questionnaire were asked to take
part in a face-to-face consensus meeting on 29 September 2015. In add-
ition, stakeholders from outside Europe could participate through a web--
conferencing interface. The aim was to reach a balanced number of
stakeholders across the four groups. Before the meeting, participants
received a personal feedback report with the results of the first question-
naire including their own relevance scores together with the group scores.
For the QIs labelled for discussion, the comments made by the stakeholders
in the first online questionnaire were shown to expedite the discussion.
During the meeting, the stakeholders discussed QIs labelled for discussion
and newly proposed QIs. Discussed QIs could be selected, rejected or
rephrased. For the rephrased QIs, modifications would typically be made to
the new wording proposal until agreement was reached between all partic-
ipating stakeholders. An audio recording of the meeting was made and
used to make sure no relevant suggestions or comments were missed dur-
ing the meeting.
Step 4 – Second questionnaire
A second web-based questionnaire including all selected and rephrased
QIs was sent to all participating stakeholders together with a personal feed-
back report (providing the results of the previous two steps of the consensus
procedure). Stakeholders were asked to appraise the QIs by answering the
question ‘Do you agree with this indicator?’ with ‘yes’ or ‘no’. Stakeholders
could select the ‘cannot assess’ answer and provide comments. Indicators
were selected if.70% of the stakeholders agreed.18
The QIs were finally categorized as (i) structure indicators reflecting or-
ganizational aspects of healthcare, (ii) process indicators describing the
care delivered to patients and (iii) outcome indicators specifying the effects
of the care given to patients according to the Donabedian model.19
Results
Figure 1 shows the results of the selection process of the inpatient
QIs (IQIs) after the different steps of the RAND-modified Delphi
method.
Step 1 – Literature and web site search
The systematic literature search identified 620 articles, of which
272 (44%) were considered eligible for full-text screening. After ex-
clusion and inclusion criteria were applied, 139 articles (22%) were
included and data extraction was performed. The flowchart of the
systematic review is shown in Figure S2. The web sites of 26 institu-
tions or organizations were searched for QIs. Eight web sites (31%)
were ultimately included for data extraction (Table S1). The sys-
tematic review and the complementary web site search led to the
identification of 518 QIs of antibiotic use in the inpatient setting.
The web site search identified 62 QIs. Systematic aggregation and
rephrasing into ‘generic’ indicators resulted in a set of 70 QIs for
appraisal by the multidisciplinary stakeholder panel (Figure 1). To
illustrate the aggregation and rephrasing process, an example is
shown. The identified QIs ‘Blood cultures performed in the emer-
gency department prior to initial antibiotic received in hospital’,
‘Proportion of community acquired pneumonia (CAP) patients who
have blood cultures drawn and proportion whose initial blood cul-
tures are performed prior to the administration or the first hospital
dose of antibiotics’, ‘Blood sample taken before start of antibiotics’
and ‘Before starting systemic antibiotic therapy, at least 2 sets of
blood cultures should be taken’ led to the generic IQI ‘IQI-31: Two
sets of blood cultures should be taken before antibiotic administra-
tion when bacteraemia is suspected’. The 70 potential QIs
were categorized into 20 themes: Access-Availability; Antibacterial
Activity; Antibacterial Spectrum; Documentation; Dosing, PK/PD,
Interval; Duration; Education; Expertise and Resources; Evidence-
Based Guidelines; Indication; Interactions; Microbiological
Diagnostics; Patient Outcome; Prescribing; Resistance Surveillance;
Route; Surgical Prophylaxis; Therapeutic Drug Monitoring; and
Timing and Toxicity.
Step 2 – First online questionnaire
In the online questionnaire, a multidisciplinary panel of 25 stake-
holders (response rate 48%) from 15 countries across four contin-
ents (n"15 from Europe, n"5 from North America, n"4 from
Asia and n"1 from Australia) appraised the relevance of the po-
tential QIs for assessing the quality of antibiotic use. The online
questionnaire is shown in Figure S3.
The 25 stakeholders were distributed as follows: n"10 (re-
sponse rate 67%) belonged to the medical community group,
including board members of national and European professional
societies, hospital pharmacists and infectious disease physicians;
n"3 (response rate 25%) to the public health and patients group,
including the WHO, the Chennai Declaration Group and the
Swedish public health institute; n"7 (response rate 50%) to the
antibiotic R&D group, including small and medium enterprises,
large pharmaceutical companies and (health) economists; and
n"5 (response rate 46%) to the payers, policy makers, govern-
ments and regulators group, including the EMA, the US CDC, gov-
ernments, a health technology assessment institute and a
national health insurance advisor. A detailed list of all the stake-
holders and their affiliations is shown in Table S2.
Based on relevance scores, 48 QIs were selected, 12 QIs were
rejected and 10 QIs were labelled for discussion (Figure 1).
Remarkably, the 12 rejected QIs included the two QIs relating to
the theme Indication. Two new potential QIs were suggested by
the stakeholders. IQIs with the highest relevance (median score of
9 and agreement score96%) score included: IQI-8 ‘An antibiotic
plan should be documented in the medical record at the start of
the antibiotic treatment’; IQI-10 ‘The results of bacteriological sus-
ceptibilities should be documented in the medical record’; IQI-23
Monnier et al.
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‘The local guidelines should correspond to the national guidelines
but should be adapted based on local resistance patterns’; IQI-26
‘An antibiotic stewardship programme should be in place at the
healthcare facility’; and IQI-47 ‘Allergy status should be taken into
account when antibiotics are prescribed’. An overview of the re-
sults of the first online questionnaire is shown in Table 1.
Step 3 – Consensus meeting
Fourteen stakeholders discussed the QIs for which there was dis-
agreement as well as the newly suggested QIs. The stakeholders
represented all groups: medical community (n"4); public health
and patients (n"1); antibiotic R&D (n" 6); and payers, policy
makers, governments and regulators (n"3). Of the 10 QIs labelled
for discussion, 3 were rephrased and 7 were rejected. The two
newly suggested indicators were rephrased. The details of the con-
sensus procedure including the selection and rejection as well as
the rephrasing of the QIs are shown in Figure 1 and Table 1.
Step 4 – Second questionnaire
Twenty-two stakeholders answered the second questionnaire (re-
sponse rate 88%). Based on agreement scores, out of the 53 po-
tential QIs, 51 were selected and 2 were rejected (Figure 1). The
final selected 51 IQIs included 36 (71%) process, 13 (25%) struc-
ture and 2 (4%) outcome indicators and have received a final
Step 1: Extraction of QIs
Systematic review n=518
Complementary web site search n=62
Total identified QIs n=580
Potential QIs
n=70
Step 2: First questionnaire
(start n=70)
48 accepted*, 10 discussion†,
2 new proposed‡, 12 rejected§
Step 3: Consensus meeting
(start n=60)
48 accepted*, 5 rephrased, 7 rejected⎪⎪
Step 4: Second questionnaire
(start n=53)
51 final accepted QIs, 2 rejected**
n=510 QIs excluded:
Duplicates
Disease-specific QIs
Footnotes
*Accepted: the potential QI was selected for the 
next round because of an overall median score or
at least 8, without disagreement. Disagreement
was defined as the case in which less than 70%
of the scores were in the upper tertile (scores 7,8
or 9).
†Discussion: the QI had a median score of at
least 8 with disagreement.
‡Added: the indicator was proposed by one of the
experts in the first survey.
§Rejected: median score lower than 8.
⎪⎪Rejected: in consensus between n=14
stakeholders.
**Rejected: agreement score<70%.
Figure 1. The results after each step of the RAND-modified Delphi method.
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numbering in Table 1. The 51 IQIs were classified into 19 themes
of responsible antibiotic use (Table 1).
Discussion
This international and multidisciplinary consensus procedure led to
the development of 51 generic QIs for antibiotic use in the inpatient
setting. These QIs are intended to be universally applicable, regard-
less of infectious disease type, geographical or socioeconomic set-
ting. Moreover, the broad background range of the stakeholders
that selected them is expected to lead to widespread support for
the QIs. Most of the IQIs were classified as process, about one-
third as structure and only two as outcome indicators according to
the Donabedian model. Altogether, the QIs covered a wide range
of 19 different themes of responsible inpatient antibiotic use, of
which the majority overlap with the elements of the definition of
responsible use.15 During the consensus procedure, the two QIs
relating to the theme ‘Indication’ were rejected by the stakeholder
panel. This is surprising as ‘Using antibiotics for the correct indica-
tion’ is one of the main recommendations for prudent use by
ECDC.20 This also contrasts with the selection of the element
‘Indication’, phrased as ‘Using antibiotics only to prevent or cure in-
fections for which antibiotic treatment provides a proven benefit’
for the global definition of responsible use by a similar international
multidisciplinary panel.15 However, the stakeholders of the present
study might have considered the requirement of a correct clin-
ical indication for the use of antibiotics being covered by six QIs
in the theme ‘Evidence-based guidelines’ (IQI-18 to IQI-22),
e.g. IQI-18 ‘Antibiotics should be prescribed according to local
practice guidelines’. In addition, several other QIs relate to the
use of guidelines (e.g. IQI-11, IQI-14, IQI-33, IQI-36). Indeed,
compliance with local hospital guidelines is a universal measure
of healthcare quality.
Other researchers have developed generic (i.e. non-disease-
specific) inpatient process QIs for antibiotic use. The QIs developed
in this study overlap with all 11 QIs identified by van den Bosch
et al.21 using a similar methodology with a European expert panel
in which all the main medical specialties involved in antibiotic
treatment were represented. However, the panel did not include
(inter)national professional clinical societies or stakeholders from
outside the medical community. In another initiative, the
Transatlantic Taskforce on Antimicrobial Resistance (TATFAR), ex-
perts from the EU and the USA identified 17 core indicators and 16
optional indicators for inpatient antibiotic use addressing the or-
ganization of ASPs.22 While the van den Bosch study aimed at de-
veloping a concise set of non-disease-specific QIs, the list of
TATFAR indicators resulted from comparisons between antibiotic
stewardship programmes in EU and US hospitals. All these QIs
should be seen as complementary output of international and
cross-disciplinary efforts to improve antibiotic use.
A strength of this work is the use of a RAND-modified Delphi
method combining both concepts from the international literature
and international stakeholder opinions. This standardized method
has been used previously for the identification of QIs of antibiotic
use in the inpatient setting.18,23,24 To our knowledge this is the first
time that the perspectives of such a broad range of stakeholders
involved with antibiotics were accounted for in the development of
the QIs. The four stakeholder groups represented all parties
involved in antibiotics from molecule to prescribed drug. The
diversity in background and geography (15 countries across four
continents) of the stakeholders emphasizes the potential for glo-
bal acceptance of our consensus. The use of a broad definition for
the inpatient setting should ensure that QIs are relevant for a large
range of healthcare facilities, including e.g. acute care hospitals
and long-term care facilities.
Methodological limitations of this study include the use of a sin-
gle literature database (MEDLINE) for the systematic review. Both
the complementary web site search and the opportunity given to
the stakeholders to propose new QIs should have ensured that no
relevant QI was missed. Another limitation is the lack of grading of
the evidence for the QIs by the authors. Instead, stakeholders
were provided with the original references for each of the QIs,
offering the opportunity to assess the scientific evidence by them-
selves. Also, there was low participation of stakeholders of the pub-
lic health and patients group compared with the three other
groups. Explanations could include the perceived lack of know-
ledge for assessing QIs for the inpatient setting as public health
typically focuses on community care. The relevance scores for the
QIs were not analysed for each individual stakeholder group separ-
ately as the aim of the study was to identify QIs taking into ac-
count different perspectives. Therefore, the data analysis was
performed across the four stakeholder groups. Finally, even
though the scope of the study was global, an English language re-
striction was applied to the literature and site searches. We may
have missed important papers in other languages. However,
English is nowadays considered a major global vehicle in the scien-
tific literature that is directed to a global audience.
Aspects relating to the applicability of the QIs in clinical practice
were not assessed in the consensus procedure. However, this may
rather have contributed to the simplicity of the QIs, required for a
global scope, including coverage of low-income settings. Certainly,
before these indicators can be used in daily medical practice, their
applicability should be tested in the prevailing healthcare setting,
including clinimetric properties relating to feasibility, validity and
reliability.23–25
How can the generic IQIs reported in this study be used? So far,
the QIs have contributed to the ‘Proposals for EU guidelines for the
Prudent Use of Antimicrobials in Human Medicine’ written by the
ECDC.20 Furthermore, educational materials derived from this
study, e.g. a podcast of a train-the-trainer event organized in col-
laboration with the BSAC with delegates from 19 EU countries, are
made available for use in ASPs and healthcare curricula.26 In the
future, the QIs, being one of the components of the DRIVE-AB
standard of responsible antibiotic use, are expected to further
guide (inter)national health policies.
In conclusion, the 51 generic QIs cover a broad scale of themes
for responsible inpatient antibiotic use. They can be used globally
to guide the use of both current and newly developed antibiotics in
the future.
Acknowledgements
The authors acknowledge Elmie Peters (Medical library, Radboud
University Medical Center) for helping with the search strategy and Sjaak
de Gouw (GGD Hollands Midden) for moderating the face-to-face con-
sensus meeting.
The authors thank the DRIVE-AB steering committee for their critical
review of the manuscript.
Monnier et al.
vi38
D
ow
nloaded from
 https://academ
ic.oup.com
/jac/article-abstract/73/suppl_6/vi30/5033636 by Leeds G
eneral Infirm
ary user on 17 Septem
ber 2019
The results of this study were presented in an oral session (presentation
number: O599) at the 26th European Congress of Clinical Microbiology and
Infectious Diseases in Amsterdam, the Netherlands, in April 2016.
Members of the DRIVE-AB WP1 group
The authors are grateful to all stakeholders that participated to the con-
sensus procedure: Ad Antonisse, Bojana Beovic, Michael Borg, Franky
Buyle, Marco Cavaleri, Harpal Dhillon, Catherine Dumartin, Richard Drew,
David Findlay, Abdul Ghafur, Lindsay Grayson, Elizabeth Hermsen, Lauri
Hicks, Philip Howard, Mike Kenston, Aaron S. Kesselheim, Charles Knirsch,
Patrick Lacor, Ramanan Laxminarayan, Mical Paul, Diamantis
Plachouras, Garyfallia Poulakou, Christian Rabaud, John H. Rex, Jesus
Rodriguez-Ba~no, Arjun Srinivasan, Cecilia Sta˚lsby Lundborg, Thomas
Ta¨ngde´n, Visanu Thamlikitkul, Alexandra Waluszewski, Sally Wellsteed,
Heiman Wertheim and Claudia Wild.
Funding
This work was supported by the Innovative Medicines Initiative (IMI) Joint
Undertaking (grant agreement no. 115618 - Driving re-investment in R&D
and responsible antibiotic use—DRIVE-AB—www.drive-ab.eu). Resources
are composed of financial contribution from the European Union’s Seventh
Framework Programme (FP7/2007–2013) and European Federation of
Pharmaceutical Industries and Associations (EFPIA) in-kind contribution.
Transparency declarations
I. C. G. reports having received educational grants from Pfizer outside the
submitted work. All other authors: none to declare.
This article is part of a Supplement sponsored by DRIVE-AB.
Supplementary data
Figures S1–S3 and Tables S1–S3 are available as Supplementary data at
JAC Online.
References
1 Laxminarayan R, Duse A, Wattal C et al. Antibiotic resistance—the need for
global solutions. Lancet Infect Dis2013;13: 1057–98.
2 de Kraker ME, Wolkewitz M, Davey PG et al. Burden of antimicrobial resist-
ance in European hospitals: excess mortality and length of hospital stay asso-
ciated with bloodstream infections due to Escherichia coli resistant to third-
generation cephalosporins. J Antimicrob Chemother2011;66: 398–407.
3 World Health Organization. The Evolving Threat of Antimicrobial
Resistance: Options for Action. http://apps.who.int/iris/bitstream/10665/
44812/1/9789241503181_eng.pdf.
4 Shlaes DM, Gerding DN, John JF et al. Society for Healthcare Epidemiology
of America and Infectious Diseases Society of America Joint Committee on
the Prevention of Antimicrobial Resistance: guidelines for the prevention of
antimicrobial resistance in hospitals.Clin Infect Dis1997;25: 584–99.
5 Report from the Invitational EU Conference on the Microbial Threat: The
Copenhagen Recommendations. http://soapimg.icecube.snowfall.se/strama/
Kopenhamnsmotet_1998.pdf.
6 Davey P, Sneddon J, Nathwani D. Overview of strategies for overcoming
the challenge of antimicrobial resistance. Expert Rev Clin Pharmacol 2010; 3:
667–86.
7 Dellit TH, Owens RC, McGowan JE Jr et al. Infectious Diseases Society of
America and the Society for Healthcare Epidemiology of America guidelines
for developing an institutional program to enhance antimicrobial steward-
ship.Clin Infect Dis2007;44: 159–77.
8 Lawrence M, Olesen F. Indicators of quality in health care. Eur J Gen Pract
1997;3: 103–8.
9 Marwick C, Watts E, Evans J et al. Quality of care in sepsis management:
development and testing of measures for improvement. J Antimicrob
Chemother2007;60: 694–7.
10 DRIVE-AB. Train-the-Trainer Event: Defining and Implementing
Responsible Antibiotic Use. http://drive-ab.eu/events/train-the-trainer-event-
defining-and-implementing-responsible-antibiotic-use/.
11 Campbell SM, Braspenning J, Hutchinson A et al. Research methods used
in developing and applying quality indicators in primary care. BMJ 2003; 326:
816–9.
12 Fitch K, Bernstein SJ, Aguilar MD et al. The RAND/UCLA Appropriateness
MethodUser’sManual. Santa Monica, CA, USA: RAND, 2001.
13 Boulkedid R, Abdoul H, Loustau M et al. Using and reporting the Delphi
method for selecting healthcare quality indicators: a systematic review. PLoS
One2011;6: e20476.
14 Orphanet. www.orpha.net/.
15 Monnier A, Eisenstein BI, Hulscher ME et al. Towards a global definition of
responsible antibiotic use: results of an international multidisciplinary consen-
sus procedure. J Antimicrob Chemother2018;73 Suppl6: vi3–vi16.
16 Oxford English Dictionary. www.oed.com.
17 Campbell SM, Cantrill JA, Roberts D. Prescribing indicators for UK general
practice: Delphi consultation study.BMJ2000;321: 425–8.
18 van den Bosch CM, Hulscher ME, Natsch S et al. Development of quality
indicators for antimicrobial treatment in adults with sepsis. BMC Infect Dis
2014;14: 345.
19 Donabedian A. The quality of care: how can it be assessed? JAMA
1988; 260: 1743–8.
20 European Centre for Disease Prevention and Control (ECDC). Proposals for
EU Guidelines on the Prudent Use of Antimicrobials in Humans. http://ecdc.
europa.eu/en/publications/_layouts/forms/Publication_DispForm.aspx?
List"4f55ad51-4aed-4d32-b960-af70113dbb90&ID"1643.
21 van den Bosch CM, Geerlings SE, Natsch S et al. Quality indicators to
measure appropriate antibiotic use in hospitalized adults. Clin Infect Dis
2015; 60: 281–91.
22 Pollack LA, Plachouras D, Sinkowitz-Cochran R et al. A concise set of struc-
ture and process indicators to assess and compare antimicrobial stewardship
programs among EU and US hospitals: results from a multinational expert
panel. Infect Control Hosp Epidemiol2016;37: 1201–11.
23 Schouten JA, Hulscher ME, Wollersheim H et al. Quality of antibiotic use
for lower respiratory tract infections at hospitals: (how) can we measure it?
Clin Infect Dis2005;41: 450–60.
24 Hermanides HS, Hulscher ME, Schouten JA et al. Development of
quality indicators for the antibiotic treatment of complicated urinary
tract infections: a first step to measure and improve care. Clin Infect Dis
2008; 46: 703–11.
25 van den Bosch CM, Hulscher ME, Natsch S et al. Applicability of generic
quality indicators for appropriate antibiotic use in daily hospital practice: a
cross-sectional point-prevalence multicenter study. Clin Microbiol Infect
2016;22: 888.e1–9.
26 Driving reinvestment in R&D for antibiotics and advocating their respon-
sible use (DRIVE-AB project). Train the Trainer Event; 26th ECCMID. http://
drive-ab.eu/wp-content/uploads/2015/06/DRIVE-AB-Train-the-Trainer-Eve
nt_Celine.pdf.
Quality indicators for antibiotic use – inpatient setting JAC
vi39
D
ow
nloaded from
 https://academ
ic.oup.com
/jac/article-abstract/73/suppl_6/vi30/5033636 by Leeds G
eneral Infirm
ary user on 17 Septem
ber 2019
